EAM Investors’s Jazz Pharmaceuticals JAZZ Stock Holding History

EAM Investors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,127	Closed	-$4.27M	–	329
2025 Q4	$4.27M	Buy	+25,127	New	+$3.85M	0.48%	105

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

EAM Investors's JAZZ Position: Q1 2026 in Review

EAM Investors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 25,127 shares — an estimated $4.27M sold.

EAM Investors first reported a position in JAZZ in Q4 2025 and held it in 1 quarter. The position peaked at $4.27M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

EAM Investors reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
EAM Investors sold 25,127 Jazz Pharmaceuticals shares in Q1 2026, an estimated $4.27M.
EAM Investors first reported a position in Jazz Pharmaceuticals in Q4 2025 and held it in 1 quarter.
EAM Investors's Jazz Pharmaceuticals position peaked at $4.27M in Q4 2025.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.